GlycoMimetics, Inc. (GLYC) News
Filter GLYC News Items
GLYC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GLYC News Highlights
- GLYC's 30 day story count now stands at 2.
- Over the past 7 days, the trend for GLYC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about GLYC are ASH and MD.
Latest GLYC News From Around the Web
Below are the latest news stories about GLYCOMIMETICS INC that investors may wish to consider to help them evaluate GLYC as an investment opportunity.
Retail investors in GlycoMimetics, Inc. (NASDAQ:GLYC) are its biggest bettors, and their bets paid off as stock gained 23% last weekKey Insights Significant control over GlycoMimetics by retail investors implies that the general public has more power... |
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaROCKVILLE, Md., December 10, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations on uproleselan, including an investigator-initiated trial (IIT) studying the first-in-class E-selectin antagonist in patients with treated secondary Acute Myeloid Leukemia (ts-AML). |
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceROCKVILLE, Md., November 09, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET. |
GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call TranscriptGlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript November 3, 2023 GlycoMimetics, Inc. reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14. Operator: Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode. Following management’s remarks, we will […] |
Q3 2023 GlycoMimetics Inc Earnings CallQ3 2023 GlycoMimetics Inc Earnings Call |
GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial ResultsCompany's Cash and Cash Equivalents Stand at $49.4 Million as of September 30, 2023 |
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023ROCKVILLE, Md., November 03, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023. Cash and cash equivalents as of September 30, 2023 were $49.4 million. |
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB). |
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023ROCKVILLE, Md., October 20, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET. |